Exchange: NASDAQ·Updated 07:43 PM EDT

VTRS News

News
all
press releases
Stocktwits Biotech Dealmaker — Viatris And GE Healthcare Buy What They Can Sell; Biohaven And Alector Sell Rights
Drugmakers this week did not purchase experimental drug candidates but invested in approved drugs and a factory that makes imaging agents.
Stocktwits
Stocktwits Biotech Dealmaker — Viatris And GE Healthcare Buy What They Can Sell; Biohaven And Alector Sell Rights
Drugmakers this week did not purchase experimental drug candidates but invested in approved drugs and a factory that makes imaging agents.
Stocktwits
More News
Deal Dispatch: Uber Buys ezCater For $2.3B, Skydance Takes Over Warner Bros., True Food Kitchen Bankruptcy
Major M&A deals this week include Viatris buys Pacira BioSciences, TowneBank acquires blueharbor, Energy Transfer buys Vacquero Midstream.read more...
Benzinga
Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio
VTRS is set to acquire PCRX for $1.65 billion in cash, adding two marketed pain therapies and a clinical-stage gene therapy candidate to expand its non-opioid pain portfolio.
Zacks
HAE, PCRX Stocks Hit Multi-Year Highs Amid Broader Market Selloff – What’s Driving The Momentum Today?
Pacira BioSciences secured a $1.65 billion buyout deal with Viatris, while Haemonetics expanded its CSL Plasma partnership, prompting BTIG to raise its price target.
Stocktwits
Viatris Bets Big on Non-Opioid Painkillers With Pacira Buyout
Pacira BioSciences stock surges 44% after Viatris announces a $1.65 billion takeover deal to expand its pain treatment portfolio.read more...
Benzinga
Helen Of Troy Posts Upbeat Q2 Earnings, Joins Pacira Biosciences, Wolfspeed And Other Big Stocks Moving Higher On Thursday
U.S. stocks fell, while Helen of Troy jumped 15.5% on strong earnings and raised guidance. Pacira soared 44.1% on Viatris acquisition news.read more...
Benzinga
Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies
Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain TherapiesPR...
PR Newswire
VTRS vs. AVTR: Which Stock Is the Better Value Option?
VTRS vs. AVTR: Which Stock Is the Better Value Option?
Zacks
Should Value Investors Buy Viatris (VTRS) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks
Viatris (VTRS) is a Top-Ranked Momentum Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks

Advertisement|Remove ads.